- Home
- ACHC vs ABUS Comparison
ACHC vs ABUS Comparison
Compare ACHC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | ABUS |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 888.5M |
| IPO Year | 2011 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ACHC | ABUS |
|---|---|---|
| Price | $17.14 | $4.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $19.71 | $5.00 |
| AVG Volume (30 Days) | ★ 3.4M | 1.8M |
| Earning Date | 04-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1258.33 | 13.64 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $3,153,963,000.00 | $6,171,000.00 |
| Revenue This Year | $6.44 | $125.30 |
| Revenue Next Year | $3.49 | N/A |
| P/E Ratio | $21.24 | ★ N/A |
| Revenue Growth | ★ 7.69 | N/A |
| 52 Week Low | $11.43 | $2.71 |
| 52 Week High | $42.85 | $5.10 |
Technical Indicators
Market Signals| Indicator | ACHC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 67.00 | 56.48 |
| Support Level | $13.02 | $4.22 |
| Resistance Level | $17.58 | $4.69 |
| Average True Range (ATR) | 0.85 | 0.24 |
| MACD | 0.33 | 0.06 |
| Stochastic Oscillator | 91.01 | 96.06 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.